Erythropoietin Market in Japan 2015-2019

Part 01: Executive summary
Highlights 
Part 02: Scope of  the report
Market overview 
Top-vendor offerings 
Part 03: Market research methodology
Research methodology 
Economic indicators 
Part 04: introduction
Key market highlights 
Part 05: Biosimilars/biologics industry
Overview 
Emerging role of biosimilars 
Factors influencing biosimilars / biologics market 
Biosimilars: business and pricing strategy 
Biosimilars industry point of view (providers, payers, buyers, vendors, regulatory bodies) 
Part 06: japan- country snapshot
Socio-economic factors 
Pharmaceutical industry in japan 
Biologics / biosimilars market in japan 
Regulatory landscape 
Healthcare reform 
Epo – addressable market in japan (epidemiology – oncology, ckd, hiv/aids, wound healing neurology) 
Part 07: Global erythropoietin market
Part 08: Market landscape
Market overview 
Market size and forecast 
Five forces analysis 
Part 09: Market segmentation by application
End stage renal disease 
Cancer 
HIV 
Wounds and neural disease 
Part 10: Market segmentation by product type
First generation erythropoietin formulation 
Second generation erythropoietin formulation 
Biosimilars 
Part 11: Market segmentation by end user
Hospitals 
Retail outlets 
Part 12: Market drivers
Part 13: Impact of drivers
Part 14: Market challenges
Part 15: Impact of drivers and challenges
Part 16: Market trends
Part 17: Vendor landscape
Competitive scenario 
Market share analysis 2014 
Other prominent vendors 
Part 18: Key vendor analysis
Chugai pharmaceuticals 
Jcr pharmaceuticals 
Kissei pharmaceutical 
Kyowa hakko kirin 
Part 19: Appendix
List of abbreviation